Abstract Number: 2861 • 2017 ACR/ARHP Annual Meeting
Treat-to-Target in Rheumatoid Arthritis: What Level of Treatment Response Is Necessary By 3 Months in Order to Achieve the Treatment Target By 6 Months? Results from the Real Life NOR-DMARD Study
Background/Purpose : In a treat-to-target strategy in rheumatoid arthritis (RA) treatment adoptions are recommended in case of poor improvement in disease activity 3 months after…Abstract Number: 2862 • 2017 ACR/ARHP Annual Meeting
Diverse Disease Activity Measures Demonstrate That the Routine Assessment of Patient Index Data with 3 Measures (Rapid-3) Assesses Only Non Inflammatory Components of Disease and Should Not be Utilized in a Treat to Target Strategy in Rheumatoid Arthritis
Background/Purpose: Treating Rheumatoid Arthritis (RA) patients to target (T2T) has been shown to result in better outcomes in patients with RA. Surrogate measures of disease…Abstract Number: 2863 • 2017 ACR/ARHP Annual Meeting
Serum Proteomic Signatures Predict Relapse in Rheumatoid Arthritis Patients Undergoing DMARD Withdrawal
Background/Purpose: Early and targeted treatment strategies have led to increasing numbers of patients with RA achieving sustained clinical remission. If and when to taper Disease…Abstract Number: 2864 • 2017 ACR/ARHP Annual Meeting
Anti-Acetylated Peptide Antibodies Positive Rheumatoid Arthritis Patients Show a More Favorable Response to Tumor-Necrosis-Factor Inhibitor Treatment and Better Disease Activity Control over Time
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have been found in rheumatoid arthritis (RA) patients and may be additional markers for diagnosis, particularly in rheumatoid factor (RF)/ anti-citrullinated…Abstract Number: 2865 • 2017 ACR/ARHP Annual Meeting
The Utility and Limitations of Serum C-Reactive Protein in Appraising Synovial Inflammation
Background/Purpose: Despite the clinical role of synovial histology in the differential diagnosis of arthritis, there are still profound unmet needs regarding predictors for diagnosis, disease…Abstract Number: 2866 • 2017 ACR/ARHP Annual Meeting
Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study
Background/Purpose: In RA-BEAM (NCT01710358), baricitinib (BARI), an oral selective inhibitor of Janus kinase (JAK) 1 and JAK 2, yielded significant improvements in patients (pts) with…Abstract Number: 2867 • 2017 ACR/ARHP Annual Meeting
CD39 Positive Regulatory T Cells As a Biomarker of Responsiveness to Methotrexate in Rheumatoid Arthritis
Background/Purpose: About 30-40% of patients with RA do not respond to MTX, the first-line therapy in RA. Early identification of responders may allow the use…Abstract Number: 2868 • 2017 ACR/ARHP Annual Meeting
Pharmacodynamic Analysis of Whole Blood Gene Expression over 2 Years in a Phase IIIb Head-to-Head Trial of Abatacept and Adalimumab in Patients with RA
Background/Purpose: The head-to-head AMPLE study compared the safety and efficacy of abatacept (co-stimulatory modulator) versus adalimumab (TNFα inhibitor) for treatment of RA over 2 years.…Abstract Number: 2869 • 2017 ACR/ARHP Annual Meeting
Significant Decrease of T-Cells but Not Macrophages in the Synovium of Patients with Active Rheumatoid Arthritis after Treatment with Tocilizumab
Background/Purpose: Tocilizumab (TCZ) is an anti-IL6R monoclonal antibody approved for the treatment of Rheumatoid Arthritis (RA). There is limited data on synovial tissue histology changes.…Abstract Number: 2870 • 2017 ACR/ARHP Annual Meeting
Ex Vivo Comparison of Baricitinib, Upadacitinib, Filgotinib, and Tofacitinib for Cytokine Signaling in Human Leukocyte Subpopulations
Background/Purpose: Baricitinib (bari), an oral selective Janus kinase (JAK) 1/2 inhibitor, has been approved in the EU for the treatment of adults with moderately to…Abstract Number: 2871 • 2017 ACR/ARHP Annual Meeting
Anti-RA33 (hnRNP-A2/B1) Autoantibodies Are Associated with the Therapeutic Response to Methotrexate and Anti-TNF Treatment in Patients with Rheumatoid Arthritis
Background/Purpose: Besides the determination of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), anti-RA33 antibodies (which are directed to the nuclear antigen hnRNP-A2/B1) could be…Abstract Number: 2872 • 2017 ACR/ARHP Annual Meeting
Elevated mTORC1 Signature in B Cells from Sjögren’s Syndrome Patients: mTOR Inhibition As a Novel Therapeutic Strategy to Halt B Cell Hyperactivity
Background/Purpose: A hallmark feature of primary Sjögren’s syndrome (pSS) is B cell hyperactivity, including presence of autoantibodies, aberrant presence of B cells and plasma cells…Abstract Number: 2873 • 2017 ACR/ARHP Annual Meeting
DNA Microarray Analysis Identifies Nuclear Receptor Subfamily 4 Group a Member 2 (NR4A2) As a Novel Molecule Involved in the Pathogenesis of Sjogren’s Syndrome
Background/Purpose:Some reports on DNA microarray analysis in labial salivary glands (LSGs) of Sjögren’s syndrome (SS) and healthy controls (HCs) showed that the genes associated with…Abstract Number: 2874 • 2017 ACR/ARHP Annual Meeting
Thymic Stromal Lymphopoietin (TSLP) Expression Is Associated with Lymphoproliferation and Lymphoma in Primary Sjögren’s Syndrome
Background/Purpose: Primary Sjögren’s syndrome (pSS) is an autoimmune and lymphoproliferative systemic disease with B cell hyperactivity and increased risk of non-Hodgkin lymphoma (NHL) evolution. In…Abstract Number: 2875 • 2017 ACR/ARHP Annual Meeting
Molecular Features Define Unique Sjögren’s Syndrome Patient Subsets
Background/Purpose: Immunologic heterogeneity in primary Sjogren’s syndrome (pSS) poses a challenge when selecting a therapeutic for a given patients or when assembling patient cohorts for…
ACR Meeting Abstracts